Skip to content

Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies

Prophylactic Topical Epinephrine to Reduce Transbronchial Lung Biopsy-related Hemorrhage in Lung Transplant Recipients: a Prospective Double-blind Placebo-controlled Trial (PROPHylactic Epinephrine in Transbronchial Biopsy [PROPHET] Trial)

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03126968
Acronym
PROPHET
Enrollment
66
Registered
2017-04-25
Start date
2017-07-01
Completion date
2021-07-02
Last updated
2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding, Hemoptysis, Lung Transplant; Complications, Lung Transplant; Complications, Mechanical

Brief summary

Bleeding poses potential for significant complication after transbronchial lung biopsies. The investigators hypothesize that prophylactic intrabronchial instillation of topical epinephrine will reduce the likelihood of bleeding. The investigators plan a double-blind, placebo controlled trial to evaluate this hypothesis.

Detailed description

The role of prophylactic topical epinephrine in improving hemostasis and prevention of clinically-significant pulmonary hemorrhage has never been studied formally in the past, despite its common use by pulmonologists performing bronchoscopic TBLB. Lung transplant recipients undergo multiple bronchoscopies and TBLBs for surveillance and evaluation of ACR as well as lung infection, especially during the first year post-transplantation. This population may have a predilection to TBLB-related bleeding and may benefit from measures to reduce the frequency and magnitude of this relatively common complication. In the PROPHET trial, the investigators intend to assess the degree of biopsy-related bleeding, measures taken to control bleeding, and potential effects of bleeding on completion of the intended procedure in 50 bronchoscopy procedures performed on single and double lung transplant recipients, randomized to prophylactic topical epinephrine versus placebo (normal saline). The study participant, physician performing the TBLB, and independent observer reviewing the procedure recording will all be blinded to the randomization. Further use of measures to control bleeding that occurs during the procedure as well as the decision to complete the procedure as planned or to abort it prematurely will be left to the discretion of the performer. In this way, the investigators aim to elucidate a potential role of topical epinephrine in the prevention of TBLB-related airway bleeding in lung transplant recipients and assess whether the dose and volume of instillation used in the investigators' institution comprises an effective means to prevent hemorrhagic complications of TBLB. HYPOTHESIS The investigators hypothesize that prophylactic instillation of topical epinephrine prior to performance of TBLB will decrease the frequency and extent of biopsy-related hemorrhage as well as result in fewer procedures being aborted earlier than intended due to bleeding complications as well as shorter overall procedure time due to the preventive effect on bleeding. Concomitantly, the investigators hypothesize that the instillation of topical epinephrine will not be associated with a serious adverse event profile in comparison to placebo. SPECIFIC AIMS In this randomized-controlled double blind placebo controlled clinical trial post-lung transplant patients scheduled to receive bronchoscopy with TBLB as part of their routine standard of care will be randomized to receive a fixed dose and volume of topical endobronchial epinephrine versus matching volume of placebo which will be instilled into the target biopsy airway prior to performance of TBLB. This study will specifically aim at providing the following information: Aim 1: Demonstrate the feasibility of assessments of bleeding related to TBLB, including: 1. The degree of TBLB-related bleeding using a standardized grading scale used by the physician performing the procedure to quantify the degree of procedure-related bleeding. 2. The degree of TBLB-related bleeding using a standardized grading scale used by two independent observers blinded to patient data and study drug assignment who will review a video recording of the procedure to quantify the degree of procedure-related bleeding. 3. The magnitude of inter-observer variability in grading TBLB-related hemorrhage based on review of video recording of the procedure. Aim 2: Evaluate the hypothesis that prophylactic administration of topical epinephrine results in reductions in TBLB-related hemorrhage in lung transplant recipients, including: 1. The frequency of active measures taken to control pulmonary hemorrhage once it occurred. 2. The proportion of procedures completed as planned in terms of obtaining a predefined target number of biopsy specimens. 3. Comparison between single- and double-lung transplant recipients in terms of prevalence and degree of TBLB-related hemorrhage. 4. Identification of clinical factors associated with an increased or decreased risk of procedure-related hemorrhage. Aim 3: Evaluate the hypothesis that prophylactic administration of topical epinephrine affects the overall efficiency of bronchoscopy with TBLB performance, including: 1. Overall duration of the bronchoscopic procedure. 2. The proportion of procedures completed as planned in terms of number of adequate biopsies obtained as assessed by the physician performing the bronchoscopy. 3. The proportion of procedures resulting in acquisition of adequate biopsy samples that allows proper pathologic evaluation of assignment of a pathologic diagnosis. Aim 4: Explore the hypothesis that instillation of our prespecified dose and volume of topical epinephrine into the target biopsy airway is not associated with an adverse event profile that is significantly different from placebo, including: 1. The prevalence of clinically significant hemodynamic changes. 2. The prevalence of cardiac adverse events, including conduction abnormalities, arrhythmia, and myocardial ischemia. 3. The prevalence of other vascular adverse events, including stroke, mesenteric ischemia, and critical limb ischemia. 4. Identification of clinical factors associated with an increased or decreased risk of drug-related adverse events.

Interventions

DRUGTopical epinephrine

Prophylactic topical epinephrine

DRUGPlacebos

Topical placebo (normal saline)

Sponsors

University of Maryland, Baltimore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male and female subjects, ≥18 years of age. * Single- or double-lung transplant recipients scheduled for bronchoscopy with TBLB. * Willingness to sign an informed consent for study participation.

Exclusion criteria

* Age \<18 years. * Pregnancy. * Inability to understand and provide a written informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Intra-procedural Hemorrhage Grading by the Performing BronchoscopistThis outcome will be analyzed at the time of procedure performance and up to 48 hours following the procedure.Intra-procedural hemorrhage will be graded by the performing bronchoscopist according to the following scale: 1. No hemorrhage. 2. Mild hemorrhage - Any bleeding originating from the biopsy target airway requiring wedging of the bronchoscope or in and out motion in order to achieve hemostasis. 3. Moderate hemorrhage - Any bleeding originating from the biopsy target airway requiring in addition to maneuvering the bronchoscope application of iced saline or topical epinephrine or placing the patient with the bleeding lung in the dependent position. 4. Severe hemorrhage - Any bleeding originating from the biopsy target airway requiring, in addition to the above-mentioned maneuvers, early termination of the procedure or necessitating application of balloon tamponade, endotracheal intubation, application of a bronchial blocker, or use of other invasive measures to achieve hemostasis, such as bronchial artery embolization or surgical intervention.

Countries

United States

Participant flow

Recruitment details

Eligible patients undergoing bronchoscopy with transbronchial biopsies after lung transplantation were offered participation in the study.

Pre-assignment details

Patients not meeting eligibility criteria were not included. Informed consent was obtained immediately prior to the procedure. Patients were randomized in a double-blind, placebo-controlled fashion.

Participants by arm

ArmCount
Prophylactic Topical Epinephrine
Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical epinephrine in a blinded manner prior to performance of transbronchial lung biopsy. Topical epinephrine: Prophylactic topical epinephrine
33
Prophylactic Topical Epinephrine
Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical epinephrine in a blinded manner prior to performance of transbronchial lung biopsy. Topical epinephrine: Prophylactic topical epinephrine
46
Placebo
Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical placebo in the form of normal saline in a blinded manner prior to performance of transbronchial lung biopsy. Placebos: Topical placebo (normal saline)
33
Placebo
Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical placebo in the form of normal saline in a blinded manner prior to performance of transbronchial lung biopsy. Placebos: Topical placebo (normal saline)
54
Total166

Baseline characteristics

CharacteristicProphylactic Topical EpinephrinePlaceboTotal
Age, Continuous62 years64 years63.5 years
Race/Ethnicity, Customized
Race / Ethnicity
African American
10 Participants12 Participants22 Participants
Race/Ethnicity, Customized
Race / Ethnicity
Caucasian
22 Participants17 Participants39 Participants
Race/Ethnicity, Customized
Race / Ethnicity
Latino
1 Participants4 Participants5 Participants
Sex: Female, Male
Female
11 Participants12 Participants23 Participants
Sex: Female, Male
Male
22 Participants21 Participants43 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 330 / 33
other
Total, other adverse events
16 / 3318 / 33
serious
Total, serious adverse events
4 / 334 / 33

Outcome results

Primary

Intra-procedural Hemorrhage Grading by the Performing Bronchoscopist

Intra-procedural hemorrhage will be graded by the performing bronchoscopist according to the following scale: 1. No hemorrhage. 2. Mild hemorrhage - Any bleeding originating from the biopsy target airway requiring wedging of the bronchoscope or in and out motion in order to achieve hemostasis. 3. Moderate hemorrhage - Any bleeding originating from the biopsy target airway requiring in addition to maneuvering the bronchoscope application of iced saline or topical epinephrine or placing the patient with the bleeding lung in the dependent position. 4. Severe hemorrhage - Any bleeding originating from the biopsy target airway requiring, in addition to the above-mentioned maneuvers, early termination of the procedure or necessitating application of balloon tamponade, endotracheal intubation, application of a bronchial blocker, or use of other invasive measures to achieve hemostasis, such as bronchial artery embolization or surgical intervention.

Time frame: This outcome will be analyzed at the time of procedure performance and up to 48 hours following the procedure.

ArmMeasureGroupValue (COUNT_OF_UNITS)
Prophylactic Topical EpinephrineIntra-procedural Hemorrhage Grading by the Performing BronchoscopistSevere or very severe hemorrhage4 Procedures
Prophylactic Topical EpinephrineIntra-procedural Hemorrhage Grading by the Performing BronchoscopistModerate, severe, or very severe hemorrhage11 Procedures
Prophylactic Topical EpinephrineIntra-procedural Hemorrhage Grading by the Performing BronchoscopistUnblinded administration of epinephrine for bleeding8 Procedures
Prophylactic Topical EpinephrineIntra-procedural Hemorrhage Grading by the Performing BronchoscopistEarly termination of the procedure due to bleeding4 Procedures
PlaceboIntra-procedural Hemorrhage Grading by the Performing BronchoscopistEarly termination of the procedure due to bleeding13 Procedures
PlaceboIntra-procedural Hemorrhage Grading by the Performing BronchoscopistSevere or very severe hemorrhage13 Procedures
PlaceboIntra-procedural Hemorrhage Grading by the Performing BronchoscopistUnblinded administration of epinephrine for bleeding20 Procedures
PlaceboIntra-procedural Hemorrhage Grading by the Performing BronchoscopistModerate, severe, or very severe hemorrhage24 Procedures

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026